BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15664861)

  • 1. Benzimidazole derivatives as novel nonpeptide luteinizing hormone-releasing hormone (LHRH) antagonists. Part 2: Benzimidazole-5-sulfonamides.
    Li Y; Kataoka M; Tatsuta M; Yasoshima K; Yura T; Urbahns K; Kiba A; Yamamoto N; Gupta JB; Hashimoto K
    Bioorg Med Chem Lett; 2005 Feb; 15(3):805-7. PubMed ID: 15664861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benzimidazole derivatives as novel nonpeptide luteinizing hormone-releasing hormone (LHRH) antagonists. Part 1: Benzimidazole-5-sulfonamides.
    Hashimoto K; Tatsuta M; Kataoka M; Yasoshima K; Shogase Y; Shimazaki M; Yura T; Li Y; Yamamoto N; Gupta JB; Urbahns K
    Bioorg Med Chem Lett; 2005 Feb; 15(3):799-803. PubMed ID: 15664860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benzimidazoles as non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists. Part 3: Discovery of 1-(1H-benzimidazol-5-yl)-3-tert-butylurea derivatives.
    Tatsuta M; Kataoka M; Yasoshima K; Sakakibara S; Shogase Y; Shimazaki M; Yura T; Li Y; Yamamoto N; Gupta J; Urbahns K
    Bioorg Med Chem Lett; 2005 May; 15(9):2265-9. PubMed ID: 15837306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzimidazole-5-sulfonamides as novel nonpeptide luteinizing hormone releasing hormone (LHRH) antagonists: minimization of mechanism-based CYP3A4 inhibition.
    Hashimoto K; Kataoka M; Tatsuta M; Yasoshima K; Yamamoto M; Yura T; Yamamoto N; Urbahns K; Gupta JB; Li Y
    Chem Pharm Bull (Tokyo); 2005 Oct; 53(10):1314-7. PubMed ID: 16204990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parallel synthesis of 2-aryl-4-aminobenzimidazoles and their evaluation as gonadotropin releasing hormone antagonists.
    Green DM; Goljer I; Andraka DS; Chengalvala M; Shanno L; Hurlburt W; Pelletier JC
    J Comb Chem; 2009; 11(1):117-25. PubMed ID: 19049392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists.
    Ogino Y; Ohtake N; Nagae Y; Matsuda K; Ishikawa M; Moriya M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4997-5001. PubMed ID: 18752943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-(2-Pyridyl)piperazine-1-benzimidazoles as potent TRPV1 antagonists.
    Shao B; Huang J; Sun Q; Valenzano KJ; Schmid L; Nolan S
    Bioorg Med Chem Lett; 2005 Feb; 15(3):719-23. PubMed ID: 15664844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule antagonists of the gonadotropin-releasing hormone (GnRH) receptor: structure-activity relationships of small heterocyclic groups appended to the 2-phenyl-4-piperazinyl-benzimidazole template.
    Hauze DB; Chengalvala MV; Cottom JE; Feingold IB; Garrick L; Green DM; Huselton C; Kao W; Kees K; Lundquist JT; Mann CW; Mehlmann JF; Rogers JF; Shanno L; Wrobel J; Pelletier JC
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1986-90. PubMed ID: 19251413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivatives.
    Ogino Y; Ohtake N; Nagae Y; Matsuda K; Moriya M; Suga T; Ishikawa M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5010-4. PubMed ID: 18723347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonpeptide luteinizing hormone-releasing hormone antagonists derived from erythromycin A: design, synthesis, and biological activity of cladinose replacement analogues.
    Randolph JT; Waid P; Nichols C; Sauer D; Haviv F; Diaz G; Bammert G; Besecke LM; Segreti JA; Mohning KM; Bush EN; Wegner CD; Greer J
    J Med Chem; 2004 Feb; 47(5):1085-97. PubMed ID: 14971889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and SAR of potent and selective androgen receptor antagonists: 5,6-Dichloro-benzimidazole derivatives.
    Ng RA; Guan J; Alford VC; Lanter JC; Allan GF; Sbriscia T; Linton O; Lundeen SG; Sui Z
    Bioorg Med Chem Lett; 2007 Feb; 17(3):784-8. PubMed ID: 17095226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors.
    Hasegawa M; Nishigaki N; Washio Y; Kano K; Harris PA; Sato H; Mori I; West RI; Shibahara M; Toyoda H; Wang L; Nolte RT; Veal JM; Cheung M
    J Med Chem; 2007 Sep; 50(18):4453-70. PubMed ID: 17676829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists.
    Bai R; Wei Z; Liu J; Xie W; Yao H; Wu X; Jiang J; Wang Q; Xu J
    Bioorg Med Chem; 2012 Aug; 20(15):4661-7. PubMed ID: 22750010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of orally efficacious benzimidazoles as melanin-concentrating hormone receptor 1 antagonists.
    Wu WL; Burnett DA; Caplen MA; Domalski MS; Bennett C; Greenlee WJ; Hawes BE; O'Neill K; Weig B; Weston D; Spar B; Kowalski T
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3674-8. PubMed ID: 16690315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic.
    Combs AP; Zhu W; Crawley ML; Glass B; Polam P; Sparks RB; Modi D; Takvorian A; McLaughlin E; Yue EW; Wasserman Z; Bower M; Wei M; Rupar M; Ala PJ; Reid BM; Ellis D; Gonneville L; Emm T; Taylor N; Yeleswaram S; Li Y; Wynn R; Burn TC; Hollis G; Liu PC; Metcalf B
    J Med Chem; 2006 Jun; 49(13):3774-89. PubMed ID: 16789735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinazoline and benzimidazole MCH-1R antagonists.
    Arienzo R; Cramp S; Dyke HJ; Lockey PM; Norman D; Roach AG; Smith P; Wong M; Wren SP
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1403-7. PubMed ID: 17178222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structure-activity relationship of imidazo[1,2-a]benzimidazoles as corticotropin-releasing factor 1 receptor antagonists.
    Han X; Pin SS; Burris K; Fung LK; Huang S; Taber MT; Zhang J; Dubowchik GM
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4029-32. PubMed ID: 15982881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors.
    Wallace MB; Feng J; Zhang Z; Skene RJ; Shi L; Caster CL; Kassel DB; Xu R; Gwaltney SL
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2362-7. PubMed ID: 18346892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piperazine derivatives of benzimidazole as potential anthelmintics. Part 1: Synthesis and activity of methyl-5-(4-substituted piperazin-1-yl)benzimidazole-2-carbamates.
    Sánchez-Alonso RM; Raviña E; Santana L; García-Mera G; Sanmartín M; Baltar P
    Pharmazie; 1989 Sep; 44(9):606-7. PubMed ID: 2608706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-(2,2,2-Trifluoroethyl)-5,6-dichlorobenzimidazole derivatives as potent androgen receptor antagonists.
    Ng RA; Guan J; Alford VC; Lanter JC; Allan GF; Sbriscia T; Lundeen SG; Sui Z
    Bioorg Med Chem Lett; 2007 Feb; 17(4):955-8. PubMed ID: 17134895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.